1Wong N,Bush K. In utero arterial thrombosis treated with re- combinant tissue plasminogen activator in an infant of a diabet- ic mother: a case report and literature review[J] Can J Plast Surg, 2012, 20(4) : e51-e52.
3Slim K,Nini E,Forestier D,et al. Methodological index for non- randomized studies (minors):development and validation of a new instrument[J]. ANZ J Surg,2003,73(9) :712-716.
4Patel GS, Jain K, Kumar R, et al.Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port- chamber catheters by complication and cost for patients receiving chemotherapy for non- haematological malignancies[ J ]. Support Care Cancer, 2014,22( 1 ) : 121 - 128.
5Schag CC,Heinrich RL,Ganz PA.Karnofsky performance status revisited: reliability, validity, and guidelines [ J ].J Clin Oncol, 1984,2 (3) : 187-193.
6Freire MP, Pierrotti LC,Zerati AE,et al.Infection related to implantable central venous access devices in cancer patients: epidemiology and risk factors [J].Infect Control Hosp Epidemiol, 2013,34(7):671-677.
7Lin CH, Wu HS, Chan DC, et al.The mechanisms of failure of totally implantable central venous access system: analysis of 73 cases with fracture of catheter[ J ]. Eur J Surg Oncol, 2010,36( 1 ) : 100- 103.
8Nardueei F, Jean- Laurent M, Boulanger L, et al.Totally implantable venous access port systems and risk factors for complications: a one r year prospective study in a cancer centre [J]. Eur J Surg Oncol, 2011,37(10) :913- 918.
9Gohz JP,Scholl A,Ritter CO,et al.Peripherally placed totally implantable venous access port systems of the forearm:clinical experience in 763 consecutive patients [J]. Cardiovasc Intervent Radiol,2010,33(6) : 1159-1167.
